Novavax (NASDAQ:NVAX – Get Free Report) and Synlogic (NASDAQ:SYBX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.
Profitability
This table compares Novavax and Synlogic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Novavax | 39.19% | -673.17% | 43.53% |
| Synlogic | N/A | -26.47% | -18.00% |
Institutional and Insider Ownership
53.0% of Novavax shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Novavax | 3 | 2 | 5 | 0 | 2.20 |
| Synlogic | 1 | 0 | 0 | 0 | 1.00 |
Novavax presently has a consensus target price of $11.88, indicating a potential upside of 46.24%. Given Novavax’s stronger consensus rating and higher probable upside, equities analysts clearly believe Novavax is more favorable than Synlogic.
Risk & Volatility
Novavax has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Earnings & Valuation
This table compares Novavax and Synlogic”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Novavax | $1.12 billion | 1.18 | $440.30 million | $2.41 | 3.37 |
| Synlogic | $8,000.00 | 912.67 | -$23.36 million | ($0.08) | -7.81 |
Novavax has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Summary
Novavax beats Synlogic on 10 of the 14 factors compared between the two stocks.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
About Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
